Prula-cel Extends the Allogeneic CAR-T Autoimmune Thesis
Adicet reported Phase 1 data for prulacabtagene leucel, an allogeneic gamma-delta anti-CD20 CAR-T therapy, in systemic lupus erythematosus with or without lupus nephritis. At 12 months, 54% of evaluable patients achieved DORIS remission and…
